Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data point disclosed is the transaction price of £12.44 per Ordinary share.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid to shareholders on July 10, 2008. The specific increases in share count are as follows:
- Mr A P Witty: 25 shares
- Mrs C M Witty: 334 shares
- Mr J S Heslop: 337 shares
- Mrs P A Heslop: 81 shares
- Mr D Learmouth: 78 shares
- Dr D Pulman: 151 shares
- Mrs C R Pulman: 50 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors and connected persons post-transaction.
- Confirm the dividend payment date of July 10, 2008, and the reinvestment mechanism used.
- Check the market price of GSK Ordinary shares on July 10, 2008, to validate the £12.44 transaction price.